BioNTech SE (BNTX) vs Merck KGaA (MRK.DE)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BNTX | MRK.DE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Size band | LARGE | LARGE |
| Listing | Nasdaq GS | XETRA |
| Country | Germany | Germany |
| Theme | oncology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $86.86 | 144.35 EUR |
| Return · 1 week | −2.63% | +4.91% |
| Return · 1 month | −12.33% | +8.86% |
| Return · 3 months | −6.05% | +5.44% |
| Return · year to date | −10.17% | +21.39% |
| Return · 1 year | −18.10% | +30.36% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −29.95% | −2.99% |
| 52-week high | $124.00 | 148.80 EUR |
| 52-week low | $79.52 | 100.70 EUR |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $21.82B | $66.19B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $90.79M | $33.79M |
| Employees | 7,807 | 62,136 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 26.42× |
| Price to earnings · forward | n/a (negative forward earnings) | 16.13× |
| Price to sales | 8.35× | 2.96× |
| Price to book | 1.11× | 2.07× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 12.87× |
| Enterprise value to revenue | 3.39× | 3.40× |
| PEG ratio | n/a (negative earnings) | 2.33 |
| Earnings per share · trailing | -7.83 | 5.45 |
| Profitability | ||
| Gross margin | 75.47% | — |
| Operating margin | −806.63% | 13.86% |
| Profit margin | −63.64% | 11.21% |
| Return on equity | −9.30% | 8.13% |
| Return on assets | −5.41% | 4.65% |
| Growth | ||
| Revenue growth | −59.50% | +3.40% |
| Earnings growth | — | −24.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | 1.78 | 40.62 |
| Current ratio | 7.85 | 1.70 |
| Dividend yield | 0.00% | 1.52% |
| Payout ratio | 0.00% | 40.37% |
| Trend and volatility | ||
| RSI · 14 | 36.22 | 64.78 |
| ADX · 14 | 15.76 | 18.77 |
| 50-day average | $98.36 | 136.88 EUR |
| 200-day average | $97.43 | 128.57 EUR |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.68% | 2.32% |
The full BNTX analysis
Everything this table leaves out for BioNTech SE: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BNTX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BNTX analysisThe full MRK.DE analysis
Everything this table leaves out for Merck KGaA: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MRK.DE argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MRK.DE analysis